Combination of IFN-α and 5-fluorouracil induces apoptosis through IFN-α/β receptor in human hepatocellular carcinoma cells

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 1277-1286

  Kondo, Motoi ^a   Nagano, Hiroaki ^a,b   Wada, Hiroshi ^a   Damdinsuren, Bazarragchaa ^a   Yamamoto, Hirofumi ^a   Hiraoka, Nobuaki ^a   Eguchi, Hidetoshi ^a   Miyamoto, Atsushi ^a   Yamamoto, Tameyoshi ^a   Ota, Hideo ^a   Nakamura, Masato ^a   Marubashi, Shigeru ^a   Dono, Keizo ^a   Umeshita, Koji ^a   Nakamori, Shoji ^a   Sakon, Masato ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; DNA FRAGMENT; DNA NUCLEOTIDYLEXOTRANSFERASE; FLUOROURACIL; INTERFERON REGULATORY FACTOR 1; PROTEIN BCL 2; STAT1 PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; DRUG EFFICACY; DRUG POTENTIATION; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NICK END LABELING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; DNA FRAGMENTATION; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUOROURACIL; GENE EXPRESSION; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON-ALPHA; LIVER NEOPLASMS; PHOSPHOPROTEINS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, INTERFERON; STAT1 TRANSCRIPTION FACTOR; STATISTICS; TIME FACTORS; TRANS-ACTIVATORS; UP-REGULATION;

EID: 19944430939     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Grazi GL, Ercolani G, Pierangeli F, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001;234:71-8.
2. Nagasue N, Ono T, Yamanoi A, et al. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg 2001;88:515-22.
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
4. Furuse J, Iwasaki M, Yoshino M, et al. Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts. Radiology 1997;204:787-90.
5. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S319-28.
6. Ikai I, Yamaoka Y, Yamamoto Y, et al. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg 1998;227:433-9.
7. Miyamoto A, Umeshita K, Sakon M, et al. A case of advanced hepatocellular carcinoma with lung metastasis, successfully treated by a combination therapy with interferon and UFT, an oral antineoplastic agent combining tegafur and uracil. J Gastroenterol Hepatol 2000;15:1447-51.
8. Wadler S, Schwartz EL, Goldman M, Lyver A, Itri L, Wiemik PH. Preclinical and clinical studies of 5-fluorouracil (FURA) and recombinant α-2a-interferon (IFN) against gastrointestinal (GI) malignancies. Clin Res 1988;36:803A.
9. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant α-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-75.
10. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990;50:3473-86.
11. Greenblatt MS, Mangalik A, Ferguson J, Elias L. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon α. Clin Cancer Res 1995;1:615-20.
12. Kelsen D, Lovett D, Wong J, et al. Interferon α-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol 1992;10:269-74.
13. Lee KH, Lee JS, Suh C, et al. Combination of 5-fluorouracil and recombinant interferon α-2B in advanced gastric cancer. A phase I study. Am J Clin Oncol 1992;15:141-5.
14. Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002;94:435-42.
15. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 1992;182:1232-9.
16. Elias L, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1989;163:867-74.
17. Matheson DS, Green BJ, Friedman SJ, Hoar DI. Studies on the mechanism of activation of human natural killer function by interferon and inhibitors of thymidylate synthesis. Cell Immunol 1988;111:118-25.
18. Sabaawy HE, Farley T, Ahmed T, Feldman E, Abraham NG. Synergetic effects of retrovirus IFN-α gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol 1999;101:82-8.
19. Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000;6:2881-90.
20. Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002;62:69-73.
21. Damdinsuren B, Nagano H, Sakon M, et al. Interferon-β is more potent than interferon-α in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 2003;10:1184-90.
22. Yamamoto H, Soh JW, Monden T, et al. Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis. Clin Cancer Res 1999;5:1805-15.
23. Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980;40:2223-8.
24. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997;22:176-81.
25. Miyake Y, Fujiwara Y, Ohue M, et al. Quantification of micrometastases in lymph nodes of colorectal cancer using real-time fluorescence polymerase chain reaction. Int J Oncol 2000;16:289-93.
26. Miyamoto A, Nagano H, Sakon M, et al. Clinical application of quantitative analysis for detection of hematogenous spread of hepatocellular carcinoma by real-time PCR. Int J Oncol 2000;18:527-32.
27. Chandra D, Liu JW, Tang DG. Early mitochondrial activation and cytochrome c up-regulation during apoptosis. J Biol Chem 2002;277:50842-54.
28. Pals G, Pindolia K, Worsham MJ. A rapid and sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example. Mol Diagn 1999; 4:241-6.
29. 2-M arrest and results in increased apoptosis in esophageal cancer cells. Cancer Res 2001;61:3188-93.
30. Kimura Y, Shiozaki H, Doki Y, et al. Cytoplasmic β-catenin in esophageal cancers. Int J Cancer 1999;84:174-8.
31. Patt YZ, Yoffe B, Charnsangavej C, et al. Low serum α-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-α-2b. Cancer 1993;72:2574-82.
32. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-α-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998;55:39-47.
33. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-81.
34. Komorizono Y, Kohara K, Oketani M, et al. Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-α for advanced hepatocellular carcinoma: a pilot study. Dig Dis Sci 2003;48:877-81.
35. Yuen MF, Ooi CG, Hui CK, et al. A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer 2003;97:2776-82.
36. Ohrnoto K, Iguchi Y, Mimura N, et al. Combined intraarterial 5-fluorouracil and intramuscular interferon-α therapy for advanced hepatocellular carcinoma. Hepatogastroenterology 2003;50:1780-82.
37. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-6.
38. Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med 2002;2:381-92.
39. Stephanou A, Brar BK, Knight RA, Latchman DS. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 2000;7:329-30.
40. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290:989-92.
41. L, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002;8:811-6.
42. Nita ME, Nagawa H, Tominaga O, et al. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 1998;78:986-92.
43. Liu R, Page C, Beidler DR, Wicha MS, Nunez G. Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol 1999;155:1861-7.
44. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
45. Fukuda R, Ishimura N, Kushiyama Y, et al. Effectiveness of interferon-α therapy in chronic hepatitis C is associated with the amount of interferon-α receptor mRNA in the liver. J Hepatol 1997;26:455-61.
46. Mizukoshi E, Kaneko S, Yanagi M, et al. Expression of interferon α/β receptor in the liver of chronic hepatitis C patients. J Med Virol 1998;56:217-23.
47. Yatsuhashi H, Fujino T, Matsumoto T, Inoue O, Koga M, Yano M. Immunohistochemical analysis of hepatic interferon α-β receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C. J Hepatol 1999;30:995-1003.
48. Kondo M, Nagano H, Sakon M, et al. Expression of interferon α/β receptor in human hepatocellular carcinoma. Int J Oncol 2000;17:83-8.
49. Harada H, Kitagawa M, Tanaka N, et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993;259:971-4.